As reported by the BBC News, The National Institute of Clinical Excellence (NICE) will be losing its power to turn down new medicines for NHS use.
From now on, NICE will only have the power to provide advice on drugs which are effective and groups of GPs will decide whether a drug should be funded or not.
A new system called ‘value-based pricing’ will be coming into effect in 2014, which aims to make new medicines more affordable to the NHS through negotiation with pharmaceutical companies.
A Department of Health spokesperson said: “We will introduce a new system of value-based pricing which will make effective treatments affordable to the NHS.
“Our plans will ensure licensed and effective drugs are available to NHS clinicians and patients. We will focus NICE’s role on what matters most – advising clinicians on effective treatments and quality standards – rather than making decisions on whether patients should access drugs that their doctors want to prescribe.”
Andrew Dillon, chief executive of NICE, said: “We support moves to extend access to new treatments at prices which reflect the additional value to patients. NICE is the global leader in evaluating the benefits of new drugs and we anticipate being at the heart of the new arrangements.”
Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharma jobs online now.